Minahil Ali

Minahil Ali

Auto-generated profile, based on publicly available information

Minahil Ali

Allama Iqbal Medical College

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
MAMuhammad Maaz Amjad
Muhammad Maaz Amjad
MBMuaz Shehzar Bashir
Muaz Shehzar Bashir
KMKhwaja Waleed Maqbool
Khwaja Waleed Maqbool
TQTayyaba Ikram Qazi
Tayyaba Ikram Qazi
MAMinahil Ali
Minahil Ali
BKBilal Wazir Khan
Bilal Wazir Khan
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain. Methods: PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026. Phase II/III RCTs comparing carboplatin plus standard chemotherapy with standard therapy alone in TNBC were included. Primary outcomes were disease-free survival (DFS), overall survival (OS), and pathological complete response (pCR). Pooled hazard ratios (HRs) and risk ratios (RRs) were calculated using random-effects models. Results: Twenty-three trials (n = 8797) were included. Carboplatin significantly improved DFS (HR 0.68, 95% CI 0.60–0.76), OS (HR 0.65, 95% CI 0.53–0.80), and pCR (RR 1.46, 95% CI 1.30–1.64). Improvements were also observed in distant disease-free survival and recurrence-free survival. However, carboplatin was associated with increased hematological toxicities, including anemia, neutropenia, and thrombocytopenia, and higher rates of dose reduction and treatment discontinuation, though treatment-related mortality was not significant. Conclusion: Carboplatin-containing chemotherapy improves survival outcomes and pCR in TNBC. Despite increased toxicity, adverse effects are generally manageable. These findings support the incorporation of carboplatin into TNBC treatment, with careful patient selection to balance efficacy and safety.

11 September 2026 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
MAMinahil Ali
Minahil Ali
DNDaniyal Naqvi
Daniyal Naqvi

12 August 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
ARAreej Riaz
Areej Riaz
ZAZain Ul Abedin
Zain Ul Abedin
LALaiba Arif
Laiba Arif
MAMinahil Ali
Minahil Ali
KQKhola Qazi
Khola Qazi
JAJaber Hamad Jaber Amin
Jaber Hamad Jaber Amin
Despite advances in reproductive medicine, a widely acceptable male contraceptive method is still lacking, leaving the burden of birth control largely on women. As a result, female-centric methods continue to dominate global contraceptive trends, as male options are limited to condoms and vasectomy, both of which are constrained by issues related to reliability, reversibility, or social acceptability. Adoption of novel methods in this regard remains low as well due to social perceptions, myths surrounding masculinity, and concerns regarding side effects. This study was conducted as a narrative literature review to synthesize current scientific, translational, social, and ethical perspectives related to the development of male contraceptive methods. In this narrative review, we have provided a historical record of developments in the field of male contraception, from traditional methods such as condoms and vasectomy to novel hormonal and non-hormonal methods, highlighting major clinical trials along with various scientific, social, economic, ethical, and cultural barriers that impede both the development and acceptance of these novel approaches. In addition, the review explores the role of unequal gender expectations and cultural norms that discourage male participation, and the broad impact of this on reproductive health. Lastly, we discuss how pairing scientific advancements with societal norms and preferences could be pivotal in promoting shared responsibility, equity, and sustainability in reproductive health.